Corvus Pharmaceuticals Inc
corvuspharma.comWhat Do They Do?
Develops drug candidates that target immune-cell proteins for cancers and immune-mediated and inflammatory diseases, including soquelitinib for T-cell lymphomas and atopic dermatitis.
10-K for FY2025, filed Mar 12, 2026We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune…View ↗
Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell…View ↗
Since the immune cells targeted by our product candidates play a role in many diseases, our strategy is to leverage our research and…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$18MView ↗
- ▲ +125% (Loss)
- vs −$8M in Q2 FY2025
-
May 14, 2026
Presented final Phase 1 atopic dermatitis trial data
The company reported efficacy and safety results for soquelitinib across the trial cohorts.
Sources
8-K, filed May 14, 2026
On May 14, 2026, Corvus Pharmaceuticals, Inc. presented final data from its randomized, blinded, placebo-controlled Phase 1 clinical trial…View ↗
Who Do They Compete With?
Competes with Abbvie, Pfizer, Sanofi, Amgen, GSK, Lilly, Arcus Biosciences, and AstraZeneca
10-K for FY2025, filed Mar 12, 2026Soquelitinib is an investigational oral therapy in development for the treatment of immune diseases and cancer. Soquelitinib is designed to…View ↗
Loading...
